About cephalosporins
Cephalosporins are bactericidal antibiotics and act by inhibiting cell wall synthesis. They inhibit a wide variety of gram-positive and gram-negative bacteria. They are considered broad-spectrum antibiotics with similar activities to those of ampicillin. They are sometimes grouped into "generations" by their antimicrobial properties. Cephalosporin drugs can be grouped into five classes or generations. The gram-negative antimicrobial property significantly increases with each newer generation of cephalosporin.
Technavio's analysts forecast the global cephalosporin drugs market to grow at a CAGR of 3.21% over the period 2014-2019.
Covered in this report
In this report, Technavio covers the present scenario and growth prospects of the global cephalosporin drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various prescription drugs along with the generic drugs used for the treatment of various infectious diseases caused by the different strains of bacteria.
Technavio's report, Global Cephalosporin Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global cephalosporin drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key regions
• Americas
• APAC
• EMEA
Key vendors
• Allergan
• Astellas
• Bristol-Myers Squibb
• GlaxoSmithKline
• Merck
• Pfizer
• Sandoz
• Teva Pharmaceuticals
Other prominent vendors
• Abbott
• Aspen Pharmacare
• AstraZeneca
• Aurobindo Pharma
• Basilea Pharmaceuticals
• Baxter
• Biocon
• Corden Pharma
• Cornerstone Therapeutics
• Eli Lilly
• F. Hoffmann-La Roche
• Flynn Pharma
• Hospira
• Incepta Pharmaceuticals
• Johnson & Johnson
• Kyorin Pharmaceutical
• Lupin Pharmaceuticals
• Orchid Pharma
• Par Pharmaceutical
• Pernix Therapeutics
• Sanofi
• Shionogi
• Sun Pharmaceutical
• Takeda Pharma
• Theravance Biopharma
• Wockhardt
Market driver
• Special regulatory designation for pipeline molecules
• For a full, detailed list, view our report
Market challenge
• Development of drug resistance
• For a full, detailed list, view our report
Market trend
• Use of combination therapies
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
PART01: Executive summary
Highlights
PART02: Scope of the report
Market overview
Top vendor offerings
PART03: Market research methodology
Research methodology
Economic indicators
PART04: Introduction
Key market highlights
PART05: Cephalosporin overview
Introduction
Precursors of cephalosporins
Mechanism of action
General principles for use of antibiotics
Clinical uses
Epidemiology
PART06: Overview on the consumption of antibiotics
Latin America
Europe
APAC
PART07: Legislation relating to antibiotic use in the US
PART08: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART09: Market segmentation by generation of cephalosporin
First-generation cephalosporins
Second-generation cephalosporins
Third-generation cephalosporins
Fourth-generation cephalosporins
Fifth-generation cephalosporins
PART10: Market segmentation by route of administration
Injection
Oral
PART11: Geographical segmentation
Segmentation of global cephalosporin drugs market by geography
Cephalosporin drugs market in Americas
Cephalosporin drugs market in EMEA
Cephalosporin drugs market in APAC
PART12: Market drivers
Special regulatory designation for pipeline molecules
Rise in prevalence of infectious diseases
Increase in awareness
PART13: Impact of drivers
PART14: Market challenges
Development of drug resistance
High generic penetration
Weak pipeline
PART15: Impact of drivers and challenges
PART16: Market trends
Use of combination therapies
Increase in M&A
Increasing irrational use of cephalosporins
PART17: Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors
PART18: Key vendor analysis
Allergan
Astellas
Bristol-Myers Squibb
GSK
Merck
Pfizer
Sandoz
Teva Pharmaceuticals
PART19: Appendix
List of abbreviations
PART20: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Evolution of cephalosporin drugs
Exhibit 03: Overview of the activity of different generations of cephalosporin drugs
Exhibit 04: General principles involved in use of antibiotics
Exhibit 05: Estimated number of cases for nosocomial infections in the US 2011
Exhibit 06: Number of cases of E.coli in the UK 2012-2014
Exhibit 07: Legislation relating to the use of antibiotics in the US
Exhibit 08: Global cephalosporin drugs market 2014-2019 ($ millions)
Exhibit 09: Five forces analysis
Exhibit 10: Global cephalosporin drugs market segment by generation
Exhibit 11: Overview of activity of different generations of cephalosporins
Exhibit 12: Evolution of different generations of cephalosporin drugs
Exhibit 13: Global cephalosporin drugs market segment by route of administration
Exhibit 14: Different generations of cephalosporin drugs by route of administration
Exhibit 15: Global cephalosporin drugs market segment by geography 2014
Exhibit 16: Global cephalosporin drugs market revenue by geography 2014-2019 ($ millions)
Exhibit 17: Cephalosporin drugs market in Americas 2014-2019 ($ millions)
Exhibit 18: Percentage share of cephalosporin market in Americas
Exhibit 19: Percentage share of market by generation of cephalosporin in the US based on revenue 2014
Exhibit 20: Cephalosporin drugs market in EMEA 2014-2019 ($ millions)
Exhibit 21: Percentage share of cephalosporin drugs market in EMEA
Exhibit 22: Percentage share of market by generation of cephalosporin in EU based on revenue 2014
Exhibit 23: Cephalosporin drugs market in APAC 2014-2019 ($ millions)
Exhibit 24: Impact of drivers
Exhibit 25: Cephalosporin resistant strains according to the period of development of resistance
Exhibit 26: Impact of drivers and challenges
Exhibit 27: Allergan: YoY growth and revenue generated from net product sales of anti-infective drugs 2011-2013 ($ millions)
Exhibit 28: Allergan: Key takeaways
Exhibit 29: Astellas: Key takeaways
Exhibit 30: Bristol-Myers Squibb: Key takeaways
Exhibit 31: GSK: Key takeaways
Exhibit 32: Merck: Key takeaways
Exhibit 33: Pfizer: Key takeaways
Exhibit 34: Sandoz: Key takeaways
Exhibit 35: Teva Pharmaceuticals: Key takeaways
Exhibit 36: Allergan: Business segmentation by product revenue 2014
Exhibit 37: Allergan: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 38: Allergan: Geographical segmentation by revenue 2014
Exhibit 39: Astellas: Product segmentation by revenue 2015
Exhibit 40: Astellas: Product segmentation by revenue 2014 and 2015 ($ billions)
Exhibit 41: Astellas: Geographical segmentation by revenue 2015
Exhibit 42: Bristol-Myers Squibb: Segmentation by revenue 2014
Exhibit 43: Bristol-Myers Squibb: Segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 44: Bristol-Myers Squibb: Geographical segmentation by revenue 2014
Exhibit 45: GSK: Business segmentation by revenue 2014
Exhibit 46: GSK: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 47: GSK: Geographical segmentation by revenue 2014
Exhibit 48: Merck: Business segmentation by revenue 2014
Exhibit 49: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 50: Merck: Geographical segmentation by revenue 2014
Exhibit 51: Pfizer: Business segmentation by revenue 2014
Exhibit 52: Pfizer business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 53: Pfizer: Geographical segmentation by revenue 2014
Exhibit 54: Sandoz: Business segmentation by revenue 2014
Exhibit 55: Teva Pharmaceuticals: Business segmentation by revenue 2014
Exhibit 56: Teva Pharmaceuticals: Business segmentation by revenue 2013 and 2014
Exhibit 57: Teva Pharmaceuticals: Geographical segmentation by revenue 2014
